Drastic Initial Response and Subsequent Response to Two ALK Inhibitors in a Patient With a Highly Aggressive ALK-rearranged Inflammatory Myofibroblastic Tumor Arising in the Pleural Cavity

Lung Cancer - Netherlands
doi 10.1016/j.lungcan.2016.07.002
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Complete Pathological Response to Crizotinib in a Patient With ALK-rearranged Lung Adenocarcinoma

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2020English

Variable Response to ALK Inhibitors in NSCLC With a Novel MYT1L-ALK Fusion

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Partial Response to Chemotherapy in a Patient With Retroperitoneal Inflammatory Myofibroblastic Tumor

Molecular and Clinical Oncology
Cancer ResearchOncology
2016English

TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors

American Journal of Pathology
Forensic MedicinePathology
2000English

P2.17-001 Pulmonary Inflammatory Myofibroblastic Tumor With TPM4-ALK Translocation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Carcinoma of Unknown Primary With EML4‐ALK Fusion Response to ALK Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2019English

ALK Inhibition in Two Emblematic Cases of Pediatric Inflammatory Myofibroblastic Tumor: Efficacy and Side Effects

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2019English

Molecular Mechanisms of Resistance to First- And Second-Generation ALK Inhibitors in ALK-rearranged Lung Cancer

European Journal of Cancer
Cancer ResearchOncology
2016English

Dramatic Response to Alectinib in a Lung Cancer Patient With a Novel VKORC1L1-ALK Fusion and an Acquired ALK T1151K Mutation

Lung Cancer: Targets and Therapy
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy